Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer

1. Yang, J.C.-H.
2. Zhou, C.
3. Jänne, P.A.
4. Ramalingam, S.S.
5. Kim, T.M.
6. Riely, G.J.
7. Spira, A.I.
8. Piotrowska, Z.
9. Mekhail, T.
10. Garcia Campelo, M.R.
11. Felip, E.
12. Bazhenova, L.
13. Jin, S.
14. Kaur, M.
15. Diderichsen, P.M.
16. Gupta, N.
17. Bunn, V.
18. Lin, J.
19. N. Churchill, E.
20. Mehta, M.
21. Nguyen, D.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1080/14737140.2023.2157815 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

• 

Data source: Scopus